RxDoctor Payments Data

Jennifer Sevush-Garcy, MD

Neurology · Mount Kisco, NYNPI 1154616506

Payments from drug & device makers

$1,697in general payments, 2019–2025

Across 45 payments — averaging $37.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$650
  • Novartis$271
  • Genentech USA, Inc.$163
  • Biogen$156
  • Eisai Inc.$125
  • Lilly USA, LLC$125
  • plus $208 from 5 others

What the payments were for

  • Food & beverage$1,67198%
  • Education$262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,697 in reported general payments places this provider in the 50th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$248,363
Medicare patients
375
Services billed
12,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate46$61,793
QuliptaAtogepant22$30,563
RexultiBrexpiprazole12$22,926
Emgality PenGalcanezumab-Gnlm25$17,162
EliquisApixaban25$15,468
UbrelvyUbrogepant11$13,576
Memantine Hcl ErMemantine Hcl55$10,141
Tegretol XrCarbamazepine13$5,518
Gabapentin226$4,015
Rasagiline Mesylate12$3,425
Memantine Hcl74$2,867
Donepezil Hcl214$2,831
Duloxetine Hcl108$2,639
Levetiracetam73$2,563
Carbidopa-LevodopaCarbidopa/Levodopa106$2,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Eliquis$18$77,26171 claims
AbbVieQulipta, Ubrelvy$650$44,14033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,623 neurology providers in New York.

Other neurology in Mount Kisco

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →